Hormone therapy after endometrial cancer

Area of Science:

• Gynecology
• Oncology
• Endocrinology

Background:

• Endometrial carcinoma is an absolute contraindication for hormone therapy (HT).
• Despite contraindications, HT, specifically continuous combined estrogen/progestogen replacement therapy (CCEPT), has been considered for early-stage (Stage I or II) endometrial cancer.
• Risk factors for endometrial carcinoma include hypertension, obesity, PCOS, and diabetes mellitus.

Purpose of the Study:

• To review the current recommendations and considerations for hormone therapy (HT) in patients with a history of endometrial carcinoma.
• To evaluate the safety and efficacy of different HT options, including CCEPT and alternatives.
• To highlight the importance of patient counseling regarding risks and alternative treatments.

Main Methods:

• Review of existing literature and observational studies on hormone therapy use after endometrial cancer.
• Analysis of current clinical opinions and recommendations regarding HT.
• Consideration of alternative treatments for menopausal symptoms.

Main Results:

• No studies have definitively established an increased rate of recurrence or mortality with HT after early-stage endometrial cancer.
• Low-dose estrogen therapy (patches, gels) is increasingly preferred over CCEPT, especially for patients with cardiovascular risk factors and a history of endometrial cancer.
• Progestogen-only therapy is considered, but potential risks of breast cancer must be evaluated.
• Phyto-preparations, tibolone, and venlafaxine are discussed as alternatives for managing climacteric complaints.

Conclusions:

• Hormone therapy (HT) should be recommended exceptionally for patients with a history of endometrial carcinoma.
• Low-dose estrogen therapy is the preferred HT option post-hysterectomy, particularly for those with cardiovascular risk factors.
• Patients must be fully informed about the existing risks of HT and the availability of alternative treatments.